Core Viewpoint - The company, He Yu-B (02256), has seen a significant increase in stock price following the approval of its IND application for the oral PD-L1 inhibitor ABSK043 in combination with ELI LILLY's KRAS G12C inhibitor for treating KRAS G12C mutated NSCLC [1] Group 1: Stock Performance - He Yu-B's stock opened over 6% higher, reaching a historical high of 18.92 HKD, and is currently trading at 18.5 HKD with a trading volume of 56,300 HKD [1] - The stock has experienced a 3.87% increase as of the latest report [1] Group 2: Clinical Development - The IND application for the combination treatment of ABSK043 and ELI LILLY's KRAS G12C inhibitor for KRAS G12C mutated NSCLC has been approved in China [1] - The approval pertains to a Phase II clinical trial for the combination therapy [1] Group 3: Index Inclusion and Shareholder Activity - He Yu-B has been included in the MSCI Global Small Cap Index as of August 26, following the latest index review [1] - Allianz SE has increased its stake in He Yu-B from 4.81% to 5.10%, joining other notable foreign investors such as Eli Lilly Asia, Qiming Venture Partners, and Morgan Stanley [1] - The company has repurchased a total of 9.545 million shares, amounting to 75.3 million HKD, with recent buybacks of 200,000 shares on August 27 and 100,000 shares on August 28 [1]
港股异动 | 和誉-B(02256)高开逾6%破顶 公司近期迎多重利好 口服PD-L1联用戈来雷塞获批二期临床